SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001720725-22-000080
Filing Date
2022-11-10
Accepted
2022-11-10 16:12:08
Documents
66
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q oyst-20220930.htm   iXBRL 10-Q 1359558
2 EX-31.1 q32022-exhibit311xnau.htm EX-31.1 12668
3 EX-31.2 q32022-exhibit312xlochner.htm EX-31.2 12668
4 EX-32.1 q32022-exhibit321xnau.htm EX-32.1 7333
5 EX-32.2 q32022-exhibit322xlochner.htm EX-32.2 7917
  Complete submission text file 0001720725-22-000080.txt   6790922

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20220930.xsd EX-101.SCH 51081
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT oyst-20220930_cal.xml EX-101.CAL 87135
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT oyst-20220930_def.xml EX-101.DEF 259753
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20220930_lab.xml EX-101.LAB 656951
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20220930_pre.xml EX-101.PRE 421165
60 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20220930_htm.xml XML 1051158
Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39112 | Film No.: 221377285
SIC: 2836 Biological Products, (No Diagnostic Substances)